Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib plus R-CHOP for previously untreated diffuse large B-cell lymphoma
2018-003560-31Phase 2Active
- Sponsor
- Universitätsklinikum Münster
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in diffuse large B-cell lymphoma (DLBCL), sponsored by Universitätsklinikum Münster. Primary endpoints: Rate of patients with dose-limiting toxicity during cycle 1 and 2-year progression-free survival. Started Jul 2019; status: active.
02
Drugs
copanlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2018-003560-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003560-31.